HK Stock Concept Tracker | 2026 Medical Insurance and Commercial Insurance "Dual Catalogs" Released, Commercialization Chain for Innovative Drugs Accelerated (with Concept Stocks)

date
07:10 23/11/2026
avatar
GMT Eight
After the release of the dual catalogs, many listed pharmaceutical companies on the A-share and Hong Kong stock markets, disclosing the inclusion or renewal of their products. Among them, leading companies such as Hengrui Pharmaceuticals and Innovent Biologics, with their rich product portfolios, became the biggest winners in this round of catalog adjustments.
Title context: HK Stock Concept Tracker | 2026 Medical Insurance and Commercial Insurance "Dual Catalogs" Released, Commercialization Chain for Innovative Drugs Accelerated (with Concept Stocks) Text: Recently, the National Healthcare Security Administration and the Ministry of Human Resources and Social Security released the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog" and the "Commercial Health Insurance Innovative Drug Catalog" (2026). The new version of the national medical insurance drug catalog added a total of 107 drugs, of which 51 are Class 1 innovative drugs, setting a new record high in number. After the adjustment, the commercial health insurance innovative drug catalog reached 28 varieties, covering fields such as oncology, rare diseases, gene therapy, cell therapy, and radioactive microsphere therapy. The 2026 version of the commercial insurance innovative drug catalog released this time was further expanded. Among the newly added varieties are major innovative products developed by domestic companies as well as cutting-edge therapies from multinational pharmaceutical companies. The surajigene autoleucel injection developed by CARsgen Therapeutics was approved for marketing in June 2026, becoming the world's first CAR-T drug for solid tumors; the injection developed by Belief BioMed is China's first approved recombinant adeno-associated virus vector gene therapy drug, used to treat adult patients with moderate to severe hemophilia B. The commercial insurance innovative drug catalog is intended to accommodate ultra-high-value innovative drugs with clear clinical value but costs far exceeding what basic medical insurance can bear. This year, two varieties from the 2025 commercial insurance catalog were successfully transferred into the basic medical insurance catalog, and it was explicitly clarified that supportive policies such as the "three exceptions" will continue to apply for a certain period, forming a tiered payment structure of "basic medical insurance guaranteeing basic needs, commercial insurance catalog guaranteeing innovation." In 2026, two commercial insurance catalog drugs, sapropterin dihydrochloride tablets and relma-cel injection, were successfully transferred into the basic medical insurance catalog, with relma-cel injection becoming the first CAR-T drug to enter the national basic medical insurance catalog. According to disclosures by JW Therapeutics in February this year, as of 2025 it had promoted the inclusion of relma-cel in the "Huimin Bao" programs of 105 cities nationwide and in nearly 100 commercial health insurance products. It is worth noting that "sky-high-priced drugs" that previously could not enter basic medical insurance due to high prices, such as CAR-T drugs for treating lymphoma and non-factor drugs for treating hemophilia, have also been successfully included. For the A-share and Hong Kong stock pharmaceutical sectors, the implementation of the dual catalogs is not only the most important policy catalyst at year-end, but also marks that China Meheco Group's payment system is shifting from a single era of exchanging price for volume to a new stage of "tiered payment, value orientation." The commercialization certainty, valuation system, and long-term growth logic of innovative drug companies are being redefined. After the release of the dual catalogs, many listed pharmaceutical companies on the A-share and Hong Kong stock markets intensively issued announcements disclosing the inclusion or renewal of their products. Among them, leading companies such as Jiangsu Hengrui Pharmaceuticals and INNOVENT BIO, with their rich product portfolios, became the biggest winners of this round of catalog adjustment. Jiangsu Hengrui Pharmaceuticals had a total of 11 varieties involving new additions, expanded indications, or renewals, with combined sales of the related varieties in 2025 approaching RMB7 billion. INNOVENT BIO had 7 innovative drugs included, among which the blockbuster GLP-1/GCG dual-target agonist mazdutide was included for the first time and is expected to rapidly ramp up in the two major markets of weight loss and diabetes. After JUNSHI BIO's toripalimab added the indication for combination therapy for urothelial carcinoma, all 13 approved indications in mainland China achieved full medical insurance coverage, making it one of the PD-1 products with the most complete indication coverage in China and further consolidating its market position in the field of tumor immunology. For innovative drug companies in the early commercialization stage such as Sichuan Biokin Pharmaceutical and First Pharma Holdings, having products included in medical insurance in the same year they are launched means the commercialization ramp-up cycle is significantly compressed. Taking Sichuan Biokin Pharmaceutical's rhenium[177Lu]-lutetium? specifically, its loncastuximab? No: its as an example, it had just been approved for the nasopharyngeal carcinoma indication in 2026 and completed medical insurance access within the year, significantly shortening the commercialization cycle. Sinolink believes that the payment foundation for the commercialization of domestic innovative drugs has taken shape: the 2026 version of the essential drugs catalog included 16 innovative drugs for the first time and clarified equipment requirements for public hospitals at all levels, while the implementation path of the commercial insurance innovative drug catalog from policy to reimbursement is gradually being improved. The commercialization chain for innovative drugsfrom approval and launch, to hospital entry, to payment coverage and sales ramp-upis being accelerated. As of the end of October 2026, 18 drugs in the 2025 version of the commercial insurance catalog had been stocked in 1,710 medical institutions and designated retail pharmacies, driving cumulative drug sales of approximately RMB600 million, with the number of stocking institutions increasing by about 140% compared with before inclusion in the catalog. The catalytic role of the commercial insurance catalog in innovative drugs' hospital entry, stocking, and sales has begun to emerge. Related concept stocks: Jiangsu Hengrui Pharmaceuticals (01276): On November 15, Jiangsu Hengrui Pharmaceuticals announced that some of its products had been included in the national medical insurance catalog. Zemutostar tablets, ruzonorelin sodium tablets, and henagliflozin/retagliptin/metformin extended-release tablets (II) were included for the first time; the indication for rhenium[?]-labeled? specifically, the injection of retagliptin? No: added an indication and was included; hydroxychloroquine? No: was renewed and added an indication; and 7 other drugs, including proline henagliflozin tablets, were successfully renewed. INNOVENT BIO (01801): A total of 7 INNOVENT BIO products (including first-time inclusions, added indications, and renewals) were successfully included in the 2026 new version of the national medical insurance catalog. Among them, products included in medical insurance for the first time include the GCG/GLP-1 dual receptor agonist Xinermei (mazdutide injection) and the IL-23p19 inhibitor Xinmeiyue (picankibart injection); products with expanded indications include the PD-1 inhibitor Tyvyt (sintilimab injection) and the BTK small molecule inhibitor Jetpal (pirtobrutinib tablets); and the cardiovascular metabolic product Xinbile (tafolecimab injection) was successfully renewed. At present, 17 of the company's 20 marketed products have been included in the national medical insurance catalog, covering the four major fields of oncology, metabolism, autoimmune diseases, and ophthalmology. (Cailian Press reporter Yu Miao) JUNSHI BIO (01877): The indication of the company's product toripalimab injection (trade name: Tuoyi, product code: JS001) in combination with disitamab vedotin for HER2-expressing locally advanced or metastatic urothelial carcinoma was successfully included in the Class B scope of the 2026 new version of the national medical insurance catalog.